Bottoms up?

Buysiders are not ready to say biotech bottomed out in February. But investors with long-term horizons are willing to risk that the downturn could deepen to start building positions in names they previously deemed too expensive.

"Looking forward you never know 100% where the base is, but I'm willing to buy stuff here and I think there's significant upside," said Marshall Gordon of ClearBridge Investments...